Physician profile
Sam Martin
NPI 1154376788
$1,445.29
in general payments reported to CMS, 2019-2025
13 companies · $82.66 in 2025
The $82.66 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $227 · 2021: $288 · 2022: $242 · 2023: $119 · 2024: $157 · 2025: $82.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.05 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $185.61 | 2019-2024 | Belbuca, Xtampza |
| Amgen INC. | $114.06 | 2019-2022 | |
| Valinor Pharma, LLC | $66.00 | 2023-2025 | Movantik |
| Novartis Pharmaceuticals Corporation | $58.74 | 2020-2021 | |
| Redhill Biopharma INC. | $48.62 | 2020-2021 | |
| Organogenesis INC. | $18.81 | 2021 | |
| Biodelivery Sciences International, INC. | $18.62 | 2019 | |
| Lilly USA, LLC | $18.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 | |
| Sentynl Therapeutics, INC. | $13.38 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.07 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.